Applied Therapeutics Inc is a New York-based biopharmaceutical firm focused on developing innovative treatments for rare diseases affecting the central nervous system and complications arising from diabetes. Its flagship product, AT-007, is making strides in clinical trials for galactosemia, a rare metabolic disorder, with additional studies targeting other conditions like sorbitol dehydrogenase deficiency. The company is also advancing AT-001 for diabetic cardiomyopathy and AT-003 for diabetic retinopathy, showcasing its commitment to addressing unmet medical needs in both rare diseases and diabetes-related complications.